Tenaya Therapeutics, Inc. ( (TNYA) ) has released its Q4 earnings. Here is a breakdown of the information Tenaya Therapeutics, Inc. presented to its investors.
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies to address the root causes of heart disease, with a portfolio that includes treatments for both rare genetic disorders and common heart conditions.
In its latest earnings report, Tenaya Therapeutics shared significant progress in its clinical trials and financial standing. The company initiated dosing in the second cohort of its MyPEAK-1 trial for hypertrophic cardiomyopathy and expects to present data at an upcoming cardiology conference. Additionally, Tenaya secured $48.9 million in financing to extend its cash runway into mid-2026.
Key highlights from the report include promising early data from the MyPEAK-1 trial, which showed TN-201 gene therapy was well tolerated and demonstrated potential efficacy. The company is also advancing its RIDGE-1 trial for arrhythmogenic right ventricular cardiomyopathy, with initial data expected in the second half of 2025. Financially, Tenaya reported a net loss of $111.1 million for 2024, with reduced R&D and G&A expenses compared to the previous year.
Looking ahead, Tenaya remains focused on advancing its gene therapy programs and anticipates sharing further clinical data in 2025. The company’s recent financing efforts and strategic developments position it to continue its mission of delivering innovative treatments for heart disease.